Why it is timely to bring a new hormonal male contraceptive to the public – A 35‐year perspective of the authors
Andrology · 2024
DOI: 10.1111/andr.13724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Andrology, 2024. Verfasst von Ronald S Swerdloff und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, The Lundquist Institute and Harbor-UCLA Medical Center, Torrance, California, USA. Hauptthemen laut MEDLINE: Contraceptive Agents, Male, Testosterone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
This perspective provides an overview of issues needed to bring a testosterone‐progestogen combined transdermal male hormonal contraceptive to the market. Large‐scale phase 2b trials are near completion and a pivotal trial to confirm efficacy and safety has been designed. We believe we are close to accomplishing the steps necessary to bring the first male‐directed effective, safe, and reversible pharmaceutical contraceptive approach to the public. If successful, we believe it will provide a new option for couples to consider in their family planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, The Lundquist Institute and Harbor-UCLA Medical Center, Torrance, California, USA.
- Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
ORCID-Profile: Ronald S Swerdloff
Zitieren
APA
Swerdloff, R. S., & Bremner, W. J. (2024). Why it is timely to bring a new hormonal male contraceptive to the public – A 35‐year perspective of the authors. Andrology. https://doi.org/10.1111/andr.13724
Vancouver
Swerdloff RS, Bremner WJ. Why it is timely to bring a new hormonal male contraceptive to the public – A 35‐year perspective of the authors. Andrology. 2024. doi:10.1111/andr.13724
BibTeX
@article{Swerdloff2024,
author = {Swerdloff, Ronald S and Bremner, William J},
title = {Why it is timely to bring a new hormonal male contraceptive to the public – A 35‐year perspective of the authors},
journal = {Andrology},
year = {2024},
doi = {10.1111/andr.13724}
}
EUVIMED